Research Model Services
At TME Scientific, we provide comprehensive research model solutions to accelerate discovery and development across biomedical fields. From in vivo animal models to 3D organoids and engineered cell lines, our services are designed to be flexible, timely, reliable, and fully customizable. Our team combines deep scientific expertise with high-quality execution, empowering your research and supporting breakthroughs in disease understanding, drug development, and precision medicine. Each project is supported by a dedicated project manager and scientists who work closely with you to ensure scientific accuracy, timely communication, and tailored solutions that meet your research goals.
In Vivo
Animal Models
We specialize in the development of customized mouse and rat models that closely mimic human disease. With extensive experience in CDX, PDX, syngeneic (wild-type and transgenic), and humanized models, we support a wide range of research areas including oncology, immunology, and infectious disease.
In addition to custom model generation, we also offer a catalog of ready-to-use mouse models available for immediate purchase — optimized for high reliability, fast turnaround, and translational relevance.
Below are some examples of the models we offer.
Cell Line-Derived Xenograft (CDX)
Human cancer cell lines are implanted into immunodeficient mice.
Experimental Applications: Efficacy evaluation, high-throughput drug screening, tumor growth inhibition.
| Name | Base Strain | Research Application |
|---|---|---|
| huHSC-NOD-hIL15 | NOD | Studies involving human immune and hematopoietic systems; supports CDX and PDX models using human-derived cells; used for investigating NK cell development, NK cell-targeted cancer immunotherapies, and ADCC mechanisms. |
Patient-Derived Xenograft (PDX)
Tumor tissue from cancer patients are implanted into immunodeficient mice, preserving tumor heterogeneity.
Experimental Applications: Efficacy and safety studies, biomarker discovery, personalized medicine.
| Name | Base Strain | Research Application |
|---|---|---|
| huHSC-NOD-hIL15 | NOD | Studies involving human immune and hematopoietic systems; supports CDX and PDX models using human-derived cells; used for investigating NK cell development, NK cell-targeted cancer immunotherapies, and ADCC mechanisms. |
Humanized Mouse Models
Immunodeficient mice are engrafted with functional human immune cells or tissues to mimic human immune responses.
Experimental Applications: Cancer vaccine development, cell/gene therapy, human-specific immunotherapeutics.
| Name | Base Strain | Research Application |
|---|---|---|
| B6-hFOLH1 (hPSMA) | C57BL/6Ntme | Targeted drug screening, design, and assessment focusing on FOLH1; investigation of disease mechanisms and treatments for hyperhomocysteinemia; study of underlying causes and therapies for various solid tumors including prostate cancer |
| B6-hLAG3 | C57BL/6Jtme | Drug screening and development targeting LAG3; exploration of pathological processes and therapeutic strategies for cancers such as melanoma, colorectal, and non-small cell lung cancer; research on chronic infectious diseases including HIV, hepatitis B, and tuberculosis; and autoimmune disorders like rheumatoid arthritis and Hashimoto’s thyroiditis |
| B6-hFAP | C57BL/6Ntme | Screening and evaluation of drugs targeting FAP; studies on disease mechanisms and treatment approaches for malignant tumors |
| H11-hB2M & HLA-A24 | C57BL/6Ntme | Investigation of human viral infections; development and validation of novel viral vaccines; evaluation of drug and vaccine safety and immune response; studies on cancer and autoimmune disorders; analysis of human immune cell-pathogen interactions; use of syngeneic tumor transplantation models |
| H11-hB2M & HLA-A2.1 | C57BL/6Ntme | Study of human viral diseases; creation and assessment of new viral vaccines; testing safety and immunogenicity of pharmaceuticals; research into cancer and autoimmune conditions; examination of immune cell and pathogen interactions; syngeneic tumor transplantation research |
| B6-hB2M & HLA-A2.1/mB2m KO | C57BL/6N;6Jtme | Development and testing of viral vaccines; evaluation of safety and immune responses to drugs and vaccines; studies on cancer and autoimmune disease mechanisms; investigation of human immune cell interactions with pathogens; research utilizing allogeneic tumor transplantation models |
| B6-hCRBN | C57BL/6Jtme | Screening, creation, and preclinical testing of CRBN-based targeted protein degradation therapies; investigation of pathological mechanisms and therapeutic options for autosomal recessive nonsyndromic intellectual disability; research on treatments and mechanisms of multiple myeloma and other blood cancers |
| BALB/c-hCRBN | BALB/cAntme | Development, screening, and preclinical testing of therapies focused on CRBN-mediated targeted protein degradation; study of disease mechanisms and treatments for autosomal recessive nonsyndromic intellectual disability; research into therapeutic strategies for multiple myeloma and other hematologic malignancies |
| B6-hKLB | C57BL/6Ntme | Drug screening and development aimed at KLB; studies of metabolic disorder mechanisms and treatments including obesity, diabetes, and metabolic-associated steatohepatitis; investigation of inflammatory diseases and select cancers |
| B6-hFGFR1c | C57BL/6Ntme | Screening, development, and preclinical testing of FGFR1c-targeted therapeutics; research on disease mechanisms and therapeutic approaches for cancers and metabolic disorders such as obesity, diabetes, and metabolic-associated steatohepatitis |
| B6-hBAFFR (hTNFRSF13C) | C57BL/6Ntme | Drug screening, design, and evaluation targeting TNFRSF13C; investigation of immune-mediated disorders such as common variable immunodeficiency (CVID), systemic lupus erythematosus (SLE), and Sjögren’s syndrome; study of disease mechanisms and treatments for certain B cell cancers |
| B6-hIL2RA | C57BL/6Ntme | Screening and development of drugs targeting IL2RA; research on autoimmune diseases including multiple sclerosis, type 1 diabetes, and rheumatoid arthritis; studies in tumor immunology and anti-cancer therapies |
| B6-hCD40 | C57BL/6Ntme | Targeted drug screening and development for CD40; investigation of disease processes and therapeutic options in cancers, autoimmune disorders, cardiovascular diseases, and neurological conditions |
| B6-hB7-H3 (hCD276) | C57BL/6Ntme | Screening and evaluation of CD276-targeted drugs; research on mechanisms and treatment strategies for solid tumors such as breast cancer, glioblastoma, and non-small cell lung cancer; studies in cancer immunotherapy |
| B6-hC5AR1 | C57BL/6Ntme | Development and screening of drugs targeting C5AR1; study of inflammatory and autoimmune diseases including psoriasis, rheumatoid arthritis, and inflammatory bowel disease; research on neuroinflammation related to Alzheimer’s disease and some cancers |
| B6-hTROP2 (hTACSTD2) | C57BL/6Ntme | Drug screening and development focusing on TACSTD2; investigation of pathological mechanisms and therapeutic approaches for various cancers; study of gelatinous drop-like corneal dystrophy |
| B6-hOX40L (hTNFSF4) | C57BL/6Ntme | Screening, development, and preclinical testing of TNFSF4-targeted therapies; research into pathological mechanisms and treatment options for autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA); studies in cancer immunology |
| B6-hCD40LG | C57BL/6Ntme | Development and preclinical evaluation of CD40LG-targeted drugs; research on autoimmune diseases including systemic lupus erythematosus (SLE) and lupus nephritis (LN); study of cardiovascular diseases and cancer |
| B6-hPCSK9 | C57BL/6Ntme | Development and screening of PCSK9-targeted therapies; preclinical pharmacology and efficacy studies; research on metabolic conditions such as hypercholesterolemia, atherosclerosis, and coronary heart disease; investigation of neurodegenerative disorders including stroke and Alzheimer’s disease |
| B6-hVEGFA/hANGPT2 | C57BL/6Jtme | Drug screening and development targeting VEGFA and ANGPT2; mechanistic studies on tumor development and cancer progression; research on vascular disease pathogenesis and autoimmune disorders |
| B6-hTL1A/hNLRP3 | C57BL/6N;6Jtme | Drug screening, development, and evaluation targeting TL1A and NLRP3; research into mechanisms and treatments for autoimmune and inflammation-associated diseases |
| B6-hIL12B | C57BL/6Ntme | Screening, development, and preclinical testing of IL12B-targeted drugs; study of immune-related disease mechanisms and therapeutic strategies as well as cancer research |
| B6-hCD20 | C57BL/6Ntme | Screening, development, and preclinical safety and efficacy evaluation of CD20-targeted therapies; research on disease mechanisms and treatments for autoimmune disorders and cancers |
| B6-hIL23A/hIL12B | C57BL/6Ntme | Drug screening, development, and assessment focused on IL23A and IL12B; investigation of pathological mechanisms and therapeutic approaches for immune-related diseases |
| B6-hCXCR2 | C57BL/6Ntme | Drug screening and development targeting CXCR2; research on the mechanisms and treatment of inflammatory diseases and cancers |
| B6-hIL4 | C57BL/6Ntme | Study of immune regulation and Th2 responses, allergic reactions, parasitic infections, and tumor immunology; preclinical development and screening of IL4-targeted therapies; investigation of inflammation and autoimmune diseases |
| Rosa26-hHRAS | C57BL/6Jtme | Rapid in vivo carcinogenicity testing for genotoxic and non-genotoxic compounds; investigation of HRAS oncogene mutations and their effects on tumor development |
| B6-hIL6 | C57BL/6Ntme | Research on autoimmune, inflammatory, cancerous, and infectious diseases; preclinical development, screening, and evaluation of IL6-targeted drugs |
| B6-hPD-1/hVEGFA | C57BL/6Jtme | Drug screening, efficacy testing, and safety evaluation focused on human PD-1 and VEGFA; research on tumor immunotherapy and immune system mechanisms |
| B6-hIgA1 | C57BL/6Ntme | Research on B cell maturation, antibody production, and autoimmune processes; construction and testing of IgA nephropathy (IgAN) models; preclinical evaluation of IgA1-targeted therapies |
| B6-hFGF21 | C57BL/6Ntme | Screening, development, and preclinical evaluation of drugs targeting FGF21; investigation of disease mechanisms and treatment strategies for metabolic disorders such as obesity, diabetes, and metabolic-associated steatohepatitis (MASH); study of cardiovascular diseases and cancer |
| B6-hSTING1 | C57BL/6Ntme | Drug screening, development, and evaluation focusing on STING1; research on autoimmune diseases; exploration of anti-cancer therapeutics |
| B6-hIL1A | C57BL/6Ntme | Drug screening and development targeting IL1A; study of pathological mechanisms and treatment approaches for conditions including rheumatoid arthritis, ankylosing spondylitis, chronic periodontitis, Alzheimer’s and vascular dementia, diabetes, systemic sclerosis, autoimmune encephalomyelitis, cerebral infarction; investigation of other chronic inflammatory, autoimmune diseases, and certain cancers |
| B6-hCD19 | C57BL/6Ntme | Research on B cell development and function; studies on autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and B cell cancers; preclinical evaluation of anti-human CD19 CAR-T therapy, bispecific antibodies, and combination therapies; development and pharmacodynamic testing of CD19-targeted treatments |
| B6-hEGFR | C57BL/6Ntme | Drug screening, development, and evaluation targeting EGFR; study of disease mechanisms and therapies for various cancers including non-small cell lung cancer (adenocarcinoma), glioblastoma, colorectal cancer, and breast cancer |
| B6-h4-1BB (TNFRSF9) | C57BL/6Ntme | Research on cancer immunotherapy and autoimmune conditions; preclinical development, screening, and evaluation of 4-1BB agonists |
| B6-h4-1BB/hPDL1 | C57BL/6N;6Jtme | Screening, development, and evaluation of drugs targeting 4-1BB and PD-L1; investigation of cancer immunotherapy mechanisms and treatments |
| B6-hIL6RA | C57BL/6Ntme | Research on autoimmune, inflammatory, cancerous, and infectious diseases; preclinical drug development, screening, and evaluation focused on IL6RA |
| B6-hIL6/IL6RA | C57BL/6Ntme | Investigation of autoimmune, inflammation-related, cancer, and infectious diseases; preclinical studies for development, screening, and testing of drugs targeting IL6 and IL6RA |
| B6-hPDL1-V | C57BL/6Ntme | Development and screening of PD-L1-targeted therapeutics; evaluation of drug efficacy and safety; research on tumor immunotherapy and mechanisms of immune evasion |
| hCldn18.2 | C57BL/6Ntme | Development and screening of therapies targeting CLDN18.2; assessment of efficacy and safety for CLDN18.2-targeted treatments; investigation of digestive tract malignancies |
| B6-hCTLA4 | C57BL/6Ntme | Development and screening of CTLA4-targeted inhibitors and antibody drugs; evaluation of therapeutic efficacy and safety; research on tumor immunotherapy and immune system mechanisms; studies on autoimmune diseases |
| hPdcd1 (hPD-1) | C57BL/6Jtme | Development and screening of PD-1-targeted therapies; efficacy and safety assessment; evaluation of tumor immunotherapy approaches; research on immune system function and tumor immune evasion mechanisms |
| B6-hPD-1/hPD-L1 | C57BL/6tme | Screening, development, and evaluation of PD-1/PD-L1-targeted drugs; studies on the pathological mechanisms and treatment strategies for cancer immunotherapy |
| B6-hGDF15 | C57BL/6Jtme | Research on cardiovascular conditions such as heart disease; studies of metabolic disorders including diabetes and anorexia; investigation of colorectal, prostate, and other cancers; preclinical evaluation of GDF15-targeted drugs |
| Cd11b-hCD89 (FCAR) | C57BL/6Ntme | Research on immune response and autoimmune processes; development and evaluation of IgA nephropathy (IgAN) models; preclinical testing of CD89-targeted therapies; studies on tumors and infectious diseases |
| B6-hIGF1R | C57BL/6Ntme | Screening, development, and evaluation of IGF1R-targeted drugs; study of mechanisms and treatments for thyroid eye disease (TED); investigation of pathological mechanisms and therapies for growth retardation, diabetes, and cancer |
| BALB/c-hIGF1R | BALB/cAntme | Screening and development of IGF1R-targeted therapies; research on mechanisms and treatment of thyroid eye disease (TED); studies on growth retardation, diabetes, and cancer |
| B6-hPD-1/hCTLA4 | C57BL/6Ntme | Drug screening, development, and evaluation targeting PD-1 and CTLA4; investigation of pathological mechanisms and therapeutic approaches for cancers and chronic viral infections |
| B6-hBAFF (hTNFSF13B) | C57BL/6Ntme | Drug screening, development, and evaluation focusing on BAFF; studies on pathological mechanisms and treatment of autoimmune diseases and specific B cell cancers |
| B6-hBCMA (hTNFRSF17) | C57BL/6Ntme | Screening, development, and evaluation of BCMA-targeted therapies; investigation of pathological mechanisms and treatment strategies for multiple myeloma, systemic lupus erythematosus, and B cell-associated disorders |
| B6-hIL1RAP | C57BL/6Ntme | Drug screening, development, and evaluation focused on IL1RAP; research on mechanisms and therapies for cancer and inflammatory conditions |
| B6-hIL1RL1 (hIL33R) | C57BL/6Ntme | Screening, development, and evaluation of IL1RL1-targeted drugs; studies on pathological processes and treatment options for cancer, inflammation, and immune-related diseases |
| B6-hIL7R | C57BL/6Ntme | Targeted drug screening and development for IL7R; research into pathological mechanisms and therapies for autoimmune disorders, immunodeficiency, and cancer |
| B6-hITGA4 | C57BL/6Ntme | Drug screening, development, and evaluation targeting ITGA4; research on pathological mechanisms and treatment of inflammatory and autoimmune diseases |
| B6-hITGB7 | C57BL/6Ntme | Screening and development of ITGB7-targeted therapies; investigation of inflammatory and autoimmune disease mechanisms and therapeutic strategies |
| B6-hα4β7 | C57BL/6Ntme | Targeted drug development and evaluation focused on α4β7; research into pathological mechanisms and treatment of inflammatory and autoimmune diseases |
| B6-hHER2 (hERBB2) | C57BL/6Ntme | Screening, development, and evaluation of HER2-targeted therapies; research on pathological mechanisms and treatment strategies for HER2-positive cancers |
| B6-hIL4RA | C57BL/6Ntme | Investigation of immune regulation involving Th2 responses, allergic and parasitic diseases, and tumor immunology; preclinical development and evaluation of IL-4Rα-targeted treatments; studies on inflammation and autoimmune disorders |
| huHSC-NOD | NOD | Long-term studies on tumor immunity, hematopoiesis, and gene therapy applications in hematologic and infectious diseases |
| huPBMC-NOD | NOD | Short-term investigations involving mature T cells focused on tumor immunity, hematopoiesis, and gene therapy for blood and infectious diseases |
| huHSC-NOD-hIL15 | NOD | Studies on human immune and hematopoietic systems; modeling using human cell line xenografts (CDX) and patient-derived xenografts (PDX); exploration of NK cell development, tumor immunotherapy leveraging NK cells, and antibody-dependent cellular cytotoxicity (ADCC) mechanisms |
Syngeneic Models
Mouse tumor cells are implanted into genetically identical immunocompetent mice.
- Wild-Type: Standard mouse strains
- Transgenic: Genetically modified mice expressing specific genes
Experimental Applications: Efficacy studies, tumor-immune interaction research, immuno-oncology.
| Name | Base Strain | Research Application |
|---|---|---|
| H11-hB2M & HLA-A24 | C57BL/6Ntme | Investigation of human viral infections; evaluation of new viral vaccines; assessment of drug and vaccine safety and immunogenicity; studies in oncology and autoimmune disorders; analysis of human immune–pathogen interactions; and syngeneic tumor transplantation research. |
| H11-hB2M & HLA-A2.1 | C57BL/6Ntme | Research on human viral infections and vaccine development; preclinical evaluation of drug and vaccine safety and immune response; studies in cancer and autoimmune diseases; investigation of human immune cell–pathogen interactions; and syngeneic tumor model research. |
| H11-hB2M & HLA-A11 | C57BL/6Ntme | Exploration of human viral infectious diseases; design and evaluation of next-generation viral vaccines; testing the safety and immune responses of therapeutics and vaccines; investigations in oncology and autoimmune conditions; analysis of interactions between human immune cells and pathogens; and studies using syngeneic tumor transplantation models. |
Disease Models
Preclinical models designed to mimic long-term disease progression in metabolic, fibrotic, and inflammatory disorders.
| Name | Base Strain | Research Application |
|---|---|---|
| B6-hLAG3 | C57BL/6Jtme | Development and evaluation of LAG3-targeted therapies; studies on cancers such as melanoma, colorectal, and non-small cell lung cancer; investigation of chronic infections (e.g., HIV, hepatitis B, tuberculosis); autoimmune disease research. |
| B6-hIL1A | C57BL/6Ntme | Screening and development of IL1A-targeted drugs; investigation of diseases such as rheumatoid arthritis, Alzheimer’s, diabetes, systemic sclerosis, and cerebral infarction; research into chronic inflammatory diseases, autoimmune, and select cancer pathways. |
| B6-hPD-1/hCTLA4 | C57BL/6Ntme | Evaluation of PD-1/CTLA4-targeted therapies; research on cancer immunotherapy and chronic viral infection mechanisms. |
Customized Models
Description:
We develop fully customized mouse and rat models tailored to your research needs, whether it's a specific genetic modification, pathway alteration, or disease phenotype. Our team collaborates closely with you to design and deliver models that meet your experimental goals.
Experimental Applications:
Tailored disease modelling, target validation, therapeutic screening, mechanistic studies, and translational research across oncology, immunology, metabolism, and more.
Interested in building a model for your study?
Contact us to discuss your project and explore custom development options.
Genetically Engineered Mouse (GEM) Models
Description:
Mice are modified to carry specific genetic alterations—such as knockouts, knock-ins, or transgenes—to mimic human disease mechanisms at the molecular level.
Experimental Applications:
Target validation, mechanistic studies, disease progression modeling, therapeutic evaluation, and biomarker discovery.
Need More Than Mouse and Rat Models?
Through our network of GLP- and AAALAC-certified partners, we offer in vivo study support across a wide range of species – including zebrafish, rabbit, minipig, beagle dog, and non-human primates (including rhesus and cynomolgus monkeys). These models enable more predictive pharmacology and translational research.
With deep pharmacodynamics expertise and a broad library of validated disease models, our partners support everything from early target and compound evaluation to IND-enabling studies.
Ready to take your preclinical studies further? Contact us to learn more.
In Vitro
Organoid Type: Tumor Derived
Drug response profiling; tumor biology studies; personalized therapy development; respiratory oncology research.
Organoid Type: iPSC Derived - Coming Soon!
Modeling lung development and respiratory diseases (e.g., asthma, fibrosis); toxicity testing; regenerative medicine; viral infection studies (e.g., influenza, COVID-19).
Organoid Type: Tumor Derived
Study of pancreatic cancer progression; therapeutic resistance; targeted therapy screening.
Organoid Type: iPSC Derived - Coming Soon!
Differentiation into insulin-producing beta cells; diabetes modeling; drug screening for pancreatic diseases; endocrine pancreas development studies.
Organoid Type: Tumor Derived
Modeling colorectal cancers; biomarker discovery; immune-oncology and microbiome interaction studies.
Organoid Type: iPSC Derived - Coming Soon!
Modeling intestinal epithelium; inflammatory bowel disease (IBD) research; drug absorption and metabolism; microbiome-host interaction studies.
Organoid Type: Tumor Derived
Research on upper GI malignancies; testing chemotherapeutics and targeted agents.
Organoid Type: iPSC Derived - Coming Soon!
Modeling gastric and esophageal lining; studies of acid injury, ulcers, and gastric cancer; evaluation of GI-targeted therapies.
Organoid Type: Tumor Derived
Gynecologic oncology studies; therapy resistance; biomarker validation.
Organoid Type: iPSC Derived - Coming Soon!
Reproductive development research; modeling oocyte maturation and ovarian function; female fertility and hormone regulation studies.
Organoid Type: Tumor Derived
Subtype-specific breast cancer research; combination therapy evaluation; personalized medicine.
Organoid Type: iPSC Derived - Coming Soon!
Modeling mammary gland development; hormone response studies; breast cancer risk and subtype-specific differentiation research.
Organoid Type: Tumor Derived
Endometrial cancer modeling; hormone-driven cancer research; therapeutic development.
Organoid Type: iPSC Derived - Coming Soon!
Endometrial tissue modeling; studies on hormonal regulation, implantation, and uterine disorders; regenerative approaches in reproductive health.
Organoid Type: Tumor Derived
Research on cholangiocarcinoma; drug metabolism; hepatobiliary cancer modeling.
Organoid Type: iPSC Derived - Coming Soon!
Differentiation into cholangiocyte-like cells; modeling biliary diseases (e.g., cholestasis); drug metabolism and bile duct toxicity screening.
Organoid Type: Tumor Derived
Hepatocellular carcinoma modeling; liver toxicity screening; metabolism and pharmacokinetics studies.
Organoid Type: iPSC Derived - Coming Soon!
Hepatocyte differentiation for liver disease modeling (e.g., NAFLD, hepatitis); drug metabolism; hepatotoxicity screening; regenerative liver therapy research.
Organoid Type: Tumor Derived
Cardiotoxicity testing; modeling of congenital and acquired heart diseases; drug safety pharmacology.
Organoid Type: iPSC Derived - Coming Soon!
Cardiomyocyte differentiation; modeling cardiac diseases (e.g., cardiomyopathies, arrhythmias); drug-induced cardiotoxicity screening; regenerative cardiology research.
Organoid Type: Tumor Derived
Neurological disease modeling (e.g., glioblastoma, neurodegeneration); neurotoxicity screening; CNS drug discovery.
Organoid Type: iPSC Derived - Coming Soon!
Generation of neurons, astrocytes, and microglia; modeling neurological and neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s); neurotoxicity and CNS drug testing.
Organoid Type: Tumor Derived
Renal toxicity testing; modeling of kidney diseases; nephrotoxicity and drug clearance research.
Organoid Type: iPSC Derived - Coming Soon!
Differentiation into renal tubule cells; modeling kidney development and diseases (e.g., polycystic kidney disease); nephrotoxicity and drug clearance studies.
Organoid Type: Tumor Derived
We offer custom organoid models developed from either tumor-derived tissues or iPSC-derived cells, tailored to your specific disease, mutation, or tissue of interest. Designed in collaboration with your team, these models capture relevant biological features for translational research.
Organoid Type: iPSC Derived - Coming Soon!
Personalized drug testing, rare disease modelling, tumor heterogeneity studies, and customized assay development.
Organoid Models
Our organoid platform supports drug screening, disease modelling, toxicity testing, and functional genomics in physiologically relevant 3D cultures. Derived from patient or tissue-specific sources, these models mimic native tissue structure and function, making them ideal for personalized medicine, mechanistic studies, and high-content analysis.
Want to run the research yourself?
We also offer ready-to-use organoids for purchase.
Cell Line Models
We offer a full suite of cell line engineering services. Customers provide the source cells, and we generate models that are stable, tagged, inducible, primary, or fully customized to meet specific research needs. These cell lines are ideal for functional assays, drug screening, protein tracking, and target validation.
Description
Stable cell lines are genetically engineered to continuously express a gene of interest over multiple passages. These models offer long-term expression without the need for repeated transfection, ensuring consistent performance across experiments.
Research Application
Long-term gene expression studies; drug screening; target validation; functional genomics; consistent assay platforms for reproducibility.
Description
Tagged cell lines are engineered to express proteins fused with detectable markers such as fluorescent tags or epitope tags. These models enable precise visualization, tracking, and isolation of proteins in live or fixed cells.
Research Application
Protein localization and trafficking studies; live-cell imaging; real-time monitoring of gene/protein expression; interaction mapping (e.g., co-IP, FRET)
Description
Inducible cell lines are designed with regulatory systems that allow gene expression to be turned on or off in response to specific stimuli (e.g., doxycycline). This enables precise temporal control over gene function in experimental settings.
Research Application
Controlled gene expression studies; functional validation with temporal regulation; toxicity testing; pathway activation/inhibition modeling.
Description
Knock-out cell lines are engineered to permanently or conditionally disrupt specific genes, eliminating their expression. These models are essential for investigating gene function and modeling genetic disorders at the cellular level.
Research Application
Generation of gene knockout models (e.g., constitutive or inducible) for functional loss-of-function studies and mechanistic disease research.
Description
Knock-in cell lines are genetically modified to insert specific sequences—such as reporter genes, tags, or regulatory elements—at targeted genomic loci. This allows precise control and tracking of gene expression and protein function.
Research Application
Introduction of reporter genes, epitope tags, or regulatory sequences (e.g., LoxP, FRT, tetO) for gene tracking, expression analysis, and gene regulation studies. Ideal for investigating gene function, signaling pathways, and targeted therapeutic development.
Description
Primary cell line models are developed from freshly isolated human or animal tissues and cultured for short-term use without genetic modification. These cells preserve the native phenotype, genotype, and functionality of the source tissue, offering biologically relevant platforms for research.
Research Application
Physiologically relevant disease modeling; immunological assays; personalized medicine research; toxicity and efficacy testing in near-native systems.
Description
Customized cell lines are engineered based on client specifications to model specific genes, mutations, pathways, or phenotypes. These tailored models enable targeted investigation of complex biological questions with high experimental relevance.
Research Application
Tailored models for specific mutations, targets, or pathways; patient-specific disease modeling; advanced screening platforms for precision medicine development.
Predictive Models
Models designed by TME are underpinned by extensive and reliable validation data, ensuring their accuracy and robustness and supported by a substantial body of scientific literature
Customer Focused
Customized solutions meticulously designed to address your unique needs and requirements. Striving to deliver exceptional results and a tailored experience that exceeds your expectations.
Scientific Excellence
Deep and comprehensive expertise in preclinical science and model development deliver advanced and precise scientific solutions and cutting-edge models that drive progress in the field.
Trusted collaborator
Through enduring partnerships with leading pharmaceutical companies, collaborate closely on the development of innovative and groundbreaking models designed for next-generation drugs.